Search
Search Results
-
Analysis and identification of drug similarity through drug side effects and indications data
BackgroundThe measurement of drug similarity has many potential applications for assessing drug therapy similarity, patient similarity, and the...
-
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
BackgroundAdalimumab-aqvh/CHS-1420 (YUSIMRY TM ) (hereafter referred to as adalimumab-aqvh) was recently approved by the US Food and Drug...
-
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
BackgroundBAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several...
-
Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim
BackgroundPegfilgrastim-cbqv/CHS-1701 (UDENYCA ® ) (hereafter referred to as pegfilgrastim-cbqv) was approved in 2018 by the US Food and Drug...
-
Analytical Characterization for Similarity Assessment Between an Aflibercept Biosimilar SB15 and Reference Product (Eylea®)
IntroductionSB15 is a proposed biosimilar product of reference aflibercept (Eylea ® ), an approved biological drug product for retinal diseases...
-
Enhancing drug and cell line representations via contrastive learning for improved anti-cancer drug prioritization
Due to cancer’s complex nature and variable response to therapy, precision oncology informed by omics sequence analysis has become the current...
-
MNCLCDA: predicting circRNA-drug sensitivity associations by using mixed neighbourhood information and contrastive learning
BackgroundcircRNAs play an important role in drug resistance and cancer development. Recently, many studies have shown that the expressions of...
-
Anesthetic drug discovery with computer-aided drug design and machine learning
Computer-aided drug design (CADD) has emerged as a highly effective and indispensable tool for streamlining the drug discovery process, leading to...
-
Accurate and interpretable drug-drug interaction prediction enabled by knowledge subgraph learning
BackgroundDiscovering potential drug-drug interactions (DDIs) is a long-standing challenge in clinical treatments and drug developments. Recently,...
-
Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product
Background and ObjectiveABP 654 is a proposed biosimilar to ustekinumab reference product (RP), a human immunoglobulin isotype class G subclass 1...
-
Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study
Biological products, whether they are innovator products or biosimilars, can incite an immunogenic response ensuing in the development of anti-drug...
-
Protein sequence analysis in the context of drug repurposing
MotivationDrug repurposing speeds up the development of new treatments, being less costly, risky, and time consuming than de novo drug discovery....
-
SIAP: an intelligent algorithm for multiple prescription pattern recognition based on weighted similarity distances
BackgroundClinical practices have demonstrated that disease treatment can be very complex. Patients with chronic diseases often suffer from more than...
-
Network-based drug repurposing for schizophrenia
Despite recent progress, the challenges in drug discovery for schizophrenia persist. However, computational drug repurposing has gained popularity as...
-
Drug repurposing for cancer therapy
Cancer, a complex and multifactorial disease, presents a significant challenge to global health. Despite significant advances in surgical,...
-
General Framework to Quantitatively Predict Pharmacokinetic Induction Drug–Drug Interactions Using In Vitro Data
IntroductionMetabolic inducers can expose people with polypharmacy to adverse health outcomes. A limited fraction of potential drug–drug interactions...
-
Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD
ABP 959 is being developed as a biosimilar to Soliris® (eculizumab) reference product (RP), which was approved under orphan designation for a group...
-
Adaptive designs were primarily used but inadequately reported in early phase drug trials
BackgroundFaced with the high cost and limited efficiency of classical randomized controlled trials, researchers are increasingly applying adaptive...
-
Cortical structural changes of morphometric similarity network in early-onset schizophrenia correlate with specific transcriptional expression patterns
BackgroundThis study aimed to investigate the neuroanatomical subtypes among early-onset schizophrenia (EOS) patients by exploring the association...
-
Overcoming limitations in current measures of drug response may enable AI-driven precision oncology
Machine learning (ML) models of drug sensitivity prediction are becoming increasingly popular in precision oncology. Here, we identify a fundamental...
